Roche Reports Two-Year Data for Evrysdi (risdiplam) in Infants with Type 1 SMA

 Roche Reports Two-Year Data for Evrysdi (risdiplam) in Infants with Type 1 SMA

Roche Reports Two-Year Data for Evrysdi (risdiplam) in Infants with Type 1 SMA

Shots:

  • Roche reports the new 2-year data from Part 1 of the FIREFISH study assessing Evrysdi in infants aged 2-7mos. with symptomatic Type 1 SMA. The 2-year results in infants treated with Evrysdi showed that continued improvement and achieve motor milestones
  • The exploratory analysis demonstrated 88% of infants were alive and required no permanent ventilation @2yrs., 59% of infants were able to sit without support for at least 5sec., 65% had maintained upright head control, 29% can turn themselves over and 30% were able to stand with support, 71% achieved a CHOP-INTEND score of ≥40 points and all infants increased their score from 12-24mos., all infants are alive in which 100% maintained the ability to swallow and 93% were able to feed orally
  • Evrysdi is an SMN2 splicing modifier, being studied in 450 patients as part of a clinical program in SMA, with patients ranging from birth to 60yrs., and includes pre-symptomatic patients and those prior treated with other SMA-targeting therapies

Click here ­to­ read full press release/ article | Ref: Roche | Image: Forbes

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post